Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029346078> ?p ?o ?g. }
- W2029346078 endingPage "773" @default.
- W2029346078 startingPage "740" @default.
- W2029346078 abstract "Hypertension is one of the most important risk factors for atherosclerosis-related mortality and morbidity. In this document, the Hypertension Committee of the Taiwan Society of Cardiology provides new guidelines for hypertension management. The key messages are as follows. (1) The life-time risk for hypertension is 90%. (2) Both the increase in the prevalence rate and the relative risk of hypertension for causing cardiovascular events are higher in Asians than in Caucasians. (3) The control rate has been improved significantly in Taiwan from 2.4% to 21% in men, and from 5% to 29% in women in recent years (1995-2002). (4) Systolic and diastolic blood pressure (BP) = 130/80 mmHg are thresholds of treatment for high-risk patients, such as those with diabetes, chronic kidney disease, stroke, established coronary heart disease, and coronary heart disease equivalents (carotid artery disease, peripheral arterial disease, and abdominal aortic aneurysm). (5) Ambulatory and home BP monitoring correlate more closely with end-organ damage and have a stronger relationship with cardiovascular events than office BP monitoring, but the feasibility of home monitoring makes it a more attractive alternative. (6) Patients with masked hypertension have higher cardiovascular risk than those with white-coat hypertension. (7) Lifestyle changes should be encouraged in all patients, and include the following six items: S-ABCDE (Salt restriction; Alcohol limitation; Body weight reduction; Cessation of smoking; Diet adaptation; Exercise adoption). (8) When pharmacological therapy is needed, physicians should consider PROCEED (Previous experience of patient; Risk factors; Organ damage; Contraindication or unfavorable conditions; Expert or doctor judgment; Expense or cost; Delivery and compliance) to decide the optimal treatment. (9) The main benefits of antihypertensive agents are derived from lowering of BP per se, and are generally independent of the drugs being used, except that certain associated cardiovascular conditions might favor certain classes of drugs. (10) There are five major classes of drugs: thiazide diuretics; β-blockers; calcium channel blockers; angiotensin-converting enzyme inhibitors (ACEIs); and angiotensin receptor blockers (ARBs). Any one of these can be used as the initial treatment, except for β-blockers, which are only indicated in patients with heart failure, a history of coronary heart disease, and hyperadrenergic state. (11) A standard dose of any one of the five major classes of antihypertensive drugs can produce an ∼10-mmHg decrease in systolic BP (rule of 10) and a 5-mmHg decrease in diastolic BP (rule of 5), after placebo subtraction. (11) Combination therapy is frequently needed for optimal control of BP, and the amount of the decrease in BP by a two-drug combination is approximately the same as the sum of the decrease by each individual drug (∼20 mmHg in systolic BP and 10 mmHg in diastolic BP) if their mechanisms of action are independent, with the exception of the combination of ACEIs and ARBs. (13) An ACEI or ARB plus a calcium channel blocker or a diuretic (A + C or A + D) are reasonable two-drug combinations, and A+C + D is a reasonable three-drug combination, unless patients have special indications for β-blockers. (14) Single-pill (fixed-dose) combinations that contain more than one drug in a single tablet are highly recommended because they reduce pill burden and cost, and improve compliance. (15) Very elderly patients (> 80 years) should be treated without delay, but BP should be reduced gradually and more cautiously. Finally, these guidelines are not mandatory; the responsible physician's decision remains most important in hypertension management." @default.
- W2029346078 created "2016-06-24" @default.
- W2029346078 creator A5011776667 @default.
- W2029346078 creator A5012717911 @default.
- W2029346078 creator A5014620051 @default.
- W2029346078 creator A5042965924 @default.
- W2029346078 creator A5046313850 @default.
- W2029346078 creator A5055418689 @default.
- W2029346078 creator A5066049666 @default.
- W2029346078 creator A5070290389 @default.
- W2029346078 creator A5071837952 @default.
- W2029346078 creator A5078892748 @default.
- W2029346078 creator A5082752193 @default.
- W2029346078 creator A5083461099 @default.
- W2029346078 date "2010-10-01" @default.
- W2029346078 modified "2023-10-18" @default.
- W2029346078 title "2010 Guidelines of the Taiwan Society of Cardiology for the Management of Hypertension" @default.
- W2029346078 cites W122349615 @default.
- W2029346078 cites W1481523571 @default.
- W2029346078 cites W1497461844 @default.
- W2029346078 cites W1528134127 @default.
- W2029346078 cites W1550111394 @default.
- W2029346078 cites W1592471891 @default.
- W2029346078 cites W1604542334 @default.
- W2029346078 cites W180946569 @default.
- W2029346078 cites W184158732 @default.
- W2029346078 cites W1892432125 @default.
- W2029346078 cites W1965087670 @default.
- W2029346078 cites W1965708830 @default.
- W2029346078 cites W1967873574 @default.
- W2029346078 cites W1976985713 @default.
- W2029346078 cites W1977014222 @default.
- W2029346078 cites W1978290051 @default.
- W2029346078 cites W1980967898 @default.
- W2029346078 cites W1984571776 @default.
- W2029346078 cites W1989826717 @default.
- W2029346078 cites W1991790856 @default.
- W2029346078 cites W1992145371 @default.
- W2029346078 cites W1993088005 @default.
- W2029346078 cites W1994658812 @default.
- W2029346078 cites W1995158918 @default.
- W2029346078 cites W1996060956 @default.
- W2029346078 cites W1999592774 @default.
- W2029346078 cites W2001629081 @default.
- W2029346078 cites W2003209602 @default.
- W2029346078 cites W2004873902 @default.
- W2029346078 cites W2006096568 @default.
- W2029346078 cites W2010912810 @default.
- W2029346078 cites W2016342558 @default.
- W2029346078 cites W2021460176 @default.
- W2029346078 cites W2023277117 @default.
- W2029346078 cites W2025309234 @default.
- W2029346078 cites W2026021204 @default.
- W2029346078 cites W2026290526 @default.
- W2029346078 cites W2027768749 @default.
- W2029346078 cites W2028851485 @default.
- W2029346078 cites W2031011310 @default.
- W2029346078 cites W2037804032 @default.
- W2029346078 cites W2039991270 @default.
- W2029346078 cites W2043244508 @default.
- W2029346078 cites W2043859609 @default.
- W2029346078 cites W2044773944 @default.
- W2029346078 cites W2046376768 @default.
- W2029346078 cites W2046945272 @default.
- W2029346078 cites W2050476654 @default.
- W2029346078 cites W2051336281 @default.
- W2029346078 cites W2054528712 @default.
- W2029346078 cites W2054796764 @default.
- W2029346078 cites W2056893352 @default.
- W2029346078 cites W2056976690 @default.
- W2029346078 cites W2059109260 @default.
- W2029346078 cites W2063743992 @default.
- W2029346078 cites W2065232710 @default.
- W2029346078 cites W2065726373 @default.
- W2029346078 cites W2065967117 @default.
- W2029346078 cites W2066349496 @default.
- W2029346078 cites W2067402319 @default.
- W2029346078 cites W2071522837 @default.
- W2029346078 cites W2072668230 @default.
- W2029346078 cites W2072674481 @default.
- W2029346078 cites W2076448163 @default.
- W2029346078 cites W2078256111 @default.
- W2029346078 cites W2079483525 @default.
- W2029346078 cites W2079663279 @default.
- W2029346078 cites W2079814995 @default.
- W2029346078 cites W2084541141 @default.
- W2029346078 cites W2089229405 @default.
- W2029346078 cites W2090166347 @default.
- W2029346078 cites W2091805663 @default.
- W2029346078 cites W2092678169 @default.
- W2029346078 cites W2094625675 @default.
- W2029346078 cites W2096710245 @default.
- W2029346078 cites W2099301718 @default.
- W2029346078 cites W2099927691 @default.
- W2029346078 cites W2100409734 @default.
- W2029346078 cites W2100509895 @default.
- W2029346078 cites W2102773820 @default.
- W2029346078 cites W2102794110 @default.